v3.25.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]        
Revenue [1] $ 444,328 $ 647,145 $ 927,977 $ 1,286,798
Expenses        
Cost of revenue [1] 343,943 540,302 725,121 1,075,849
Selling, general and administrative expenses [1] 75,209 69,185 153,618 148,289
Depreciation and amortization expenses 23,141 29,870 47,199 59,373
Loss on lease termination 0 0 1,906 0
Change in fair value of contingent consideration 3,206 0 2,926 8,908
Total operating expenses 445,499 639,357 930,770 1,292,419
Operating income (loss) (1,171) 7,788 (2,793) (5,621)
Interest income 1,084 1,370 2,358 3,920
Interest expense (11,601) (5,995) (21,986) (11,992)
Gain (loss) from equity method investees 197 (1,700) 178 (1,394)
Extinguishment of Series A Preferred Stock (9,000) 0 (9,000) 0
Loss on option exercise (196) 0 (52,544) 0
Change in tax receivables agreement liability 0 0 0 (173)
Other expense, net (35) (105) (83) (97)
Income (loss) before income taxes (20,722) 1,358 (83,870) (15,357)
Provision for (benefit from) income taxes (825) (238) 645 327
Income (loss) before preferred dividends and accretion of Series A Preferred Stock (19,897) 1,596 (84,515) (15,684)
Dividends and accretion of Series A Preferred Stock (31,193) (7,979) (38,825) (15,924)
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (51,090) (6,383) (123,340) (31,608)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted $ (51,090) $ (6,383) $ (123,340) $ (31,608)
Loss per common share        
Basic (in dollars per share) $ (0.44) $ (0.06) $ (1.07) $ (0.28)
Diluted (in dollars per share) $ (0.44) $ (0.06) $ (1.07) $ (0.28)
Weighted-average common shares outstanding        
Basic (in shares) 115,882 114,688 115,600 114,415
Diluted (in shares) 115,882 114,688 115,600 114,415
Comprehensive loss        
Net loss attributable to common shareholders of Evolent Health, Inc. $ (51,090) $ (6,383) $ (123,340) $ (31,608)
Other comprehensive loss, net of taxes, related to:        
Foreign currency translation adjustment 22 (47) 46 (98)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. $ (51,068) $ (6,430) $ (123,294) $ (31,706)
[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.